Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Asset disposition
Director departure
Quarterly results
Auditor change
Acq. announced
Consulting agrmnt
Appointed director
Inv. presentation
LISATA THERAPEUTICS, INC. (CLBS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update",
"2 0 2 3 L"
07/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors"
05/09/2023 8-K Quarterly results
Docs: "Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update",
"2 0 2 3 L"
02/06/2023 8-K Quarterly results
11/10/2022 8-K Quarterly results
09/29/2022 8-K Quarterly results
09/22/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "NOVEL INTRATUMORAL DELIVERY TECHNOLOGY TO IMPROVE THERAPEUTIC EFFICACY OF"
09/15/2022 8-K Appointed a new director
Docs: "Certificate of Amendment (Reverse Stock Split) to the Amended and Restated Certificate of Incorporation",
"Certificate of Amendment (Name Change) to the Amended and Restated Certificate of Incorporation",
"WITNESSETH:",
"INDEMNIFICATION AGREEMENT",
"BASKING RIDGE, NJ and SAN DIEGO, CA",
"Lisata Therapeutics, Inc. Corporate Presentation, September 15, 2022"
09/14/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CALADRIUS BIOSCIENCES, INC.",
"Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics All Merger-related proposals approved at the Annual Meeting of Stockholders"
08/19/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/27/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION",
"EXHIBIT 2.2 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT",
"EXHIBIT 2.3 FORM OF CALADRIUS STOCKHOLDER SUPPORT AGREEMENT",
"EXHIBIT 2.4 FORM OF LOCK-UP AGREEMENT",
"EXHIBIT 10.1 SERIES D PREFERRED STOCK PURCHASE AGREEMENT THIS SERIES D PREFERRED STOCK PURCHASE AGREEMENT",
"EXCEPT AS OTHERWISE EXPRESSLY SPECIFIED IN THIS SECTION 5, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES HEREUNDER, WHETHER RELATING TO SERVICES, INFORMATION, INTELLECTUAL PROPERTY RIGHTS, TECHNOLOGY OR OTHERWISE, CONTEMPLATED BY THIS AGREEMENT OR OTHERWISE, AND EACH PARTY HEREBY DISCLAIMS ALL OTHER REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY,",
"Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement",
"CALADRIUS URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CALADRIUS, THE PROPOSED TRANSACTION AND RELATED MATTERS."
03/22/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update",
"CORONARY MICROVASCULAR DYSFUNCTION FREEDOM PHASE 2B TRIAL"
02/25/2022 8-K Quarterly results
02/18/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/04/2021 8-K Quarterly results
Docs: "Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results",
"PRODUCT/INDICATION DEVELOPMENT STAGE KEY MILESTONE TARGETS"
08/05/2021 8-K Quarterly results
06/16/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/19/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
01/29/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Caladrius Biosciences, Inc. Corporate Presentation, January 29, 2021"
01/25/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Warrant",
"Form of Securities Purchase Agreement",
"Form of Registration Rights Agreement",
"Caladrius Biosciences Announces $25.0 Million Private Placement"
01/11/2021 8-K Quarterly results
12/14/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Caladrius Biosciences, Inc. Corporate Presentation, December 2020",
"Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update"
11/17/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer"
11/05/2020 8-K Quarterly results, Appointed a new director
Docs: "Caladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results",
"Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors"
08/13/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
07/28/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy